Aine E Clements, MD | Gynecological ...

Dr. Aine E. Clements

Claim this profile

OhioHealth Mansfield Hospital

Studies Endometrial Cancer
Studies Ovarian Cancer
7 reported clinical trials
32 drugs studied

Area of expertise

1Endometrial Cancer
Aine E. Clements has run 4 trials for Endometrial Cancer. Some of their research focus areas include:
Stage IV
Stage III
HRAS positive
2Ovarian Cancer
Aine E. Clements has run 4 trials for Ovarian Cancer. Some of their research focus areas include:
KRAS positive
Stage IV
NRAS positive

Affiliated Hospitals

Image of trial facility.
OhioHealth Mansfield Hospital
Image of trial facility.
Riverside Methodist Hospital

Clinical Trials Aine E. Clements is currently running

Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Image of trial facility.

Selumetinib + Olaparib

for Ovarian and Endometrial Cancer

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2

More about Aine E. Clements

Clinical Trial Related2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Aine E. Clements has experience with
  • Binimetinib
  • Ipatasertib
  • Olaparib
  • Palbociclib
  • Selumetinib Sulfate
  • Everolimus

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Aine E. Clements specialize in?
Is Aine E. Clements currently recruiting for clinical trials?
Are there any treatments that Aine E. Clements has studied deeply?
What is the best way to schedule an appointment with Aine E. Clements?
What is the office address of Aine E. Clements?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security